STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

                Date of Report (Date of earliest event reported)
                                November 20, 2007

                           HEMISPHERX BIOPHARMA, INC.
             (Exact name of registrant as specified in its charter)

                           Delaware 0-27072 52-0845822
         (state or other jurisdiction (Commission File (I.R.S. Employer
                  of incorporation) Number) Identification No.)

              1617 JFK Boulevard, Philadelphia, Pennsylvania 19103
               (Address of principal executive offices) (Zip Code)

       Registrant's telephone number, including area code: (215) 988-0080

        ----------------------------------------------------------------
          (former name or former address, if changed since last report)

     Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
           following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Securities Act (17 CFR
230.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240-14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17CFR 240-13e-4(c))





Section 1 - Registrant's Business and Operations.

Item 1.01 Entry into a Material Definitive Agreement

See Item 5.02 below:

Section 5 - Corporate Governance and Management

Item 5.02  Departure of Directors or Certain  Officers;  Election of  Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 20, 2007 Steven D. Spence  submitted his resignation  from the Board
of Directors  effective  immediately.  Mr.  Spence was a member of the following
Board Committees:  The Audit Committee,  the Corporate Governance and Nomination
Committee,  and the Executive Committee.  Mr. Spence was the financial expert on
the Audit  Committee.  Mr.  Spence  stated  that his  perspective  on  corporate
strategy differed with a majority of the Board of Directors.





                                   SIGNATURES


         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
the  registrant  has duly  caused  this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                            HEMISPHERX BIOPHARMA, INC.


November 26, 2007                      By:  /s/ William A. Carter
                                            ---------------------
                                            William A. Carter, M.D.
                                            Chief Executive Officer